CAR T cell therapy for relapsed CD19 blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (or you are a child/teen with ALL ages >3 to <18, depending on the group).
- Your cancer is CD19-positive ALL, CLL, DLBCL, FL, or MCL, confirmed by lab testing (cytology and flow cytometry).
- Your disease is relapsed or refractory (including “molecular relapse” measured as MRD above the study’s threshold twice).
- You have measurable cancer/MRD at enrollment and enough time to benefit (life expectancy at least 12 weeks).
- You can safely undergo treatment based on your body function tests (kidneys, liver, lungs, heart, and blood counts).
- You are able and willing to follow pregnancy prevention rules (contraception for one year after CAR T), and you can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
This trial tests a new CAR T-cell treatment for people with certain blood cancers (like some leukemias and lymphomas) that have not responded to other treatments. It may help even if previous CD19-targeted therapies have stopped working.
Hear when a new Acute Lymphoblastic Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.